# Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

> **NCT04374877** · PHASE1 · COMPLETED · sponsor: **Coherus Oncology, Inc.** · enrollment: 145 (actual)

## Conditions studied

- Advanced Solid Tumor
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** CHS-388
- **DRUG:** Pembrolizumab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04374877
- **Lead sponsor:** Coherus Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-22
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-06-05
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374877, "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04374877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*